CRISPR Therapeutics AG
CRSP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1 |
| % Growth | -90.5% | 84,762.4% | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | -$0 | $1 |
| % Margin | -215% | 64.8% | -25,186.7% | 88.9% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | -$0 | -$0 |
| Operating Expenses | $0 | $0 | $1 | $0 |
| Operating Income | -$0 | -$0 | -$1 | $0 |
| % Margin | -1,333% | -60.1% | -154,394.7% | 40.9% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$1 | $0 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | -$0 | -$0 | -$1 | $0 |
| % Margin | -1,046.4% | -41.5% | -149,122.7% | 41.4% |
| EPS | -4.34 | -1.94 | -8.36 | 4.97 |
| % Growth | -123.7% | 76.8% | -268.2% | – |
| EPS Diluted | -4.34 | -1.94 | -8.36 | 4.7 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$1 | $0 |
| % Margin | -1,278% | -54.8% | -148,850.7% | 42.9% |